← All Oncology Institute, INC filings

Oncology Institute, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
TOI
Oncology Institute, INC
10-K: Oncology Institute Reports Strong Revenue Growth, Reduced Losses
The Oncology Institute, Inc. reported a 27.8% increase in total operating revenue for 2025, alongside a significant reduction in net loss and improved Adjusted EBITDA.
NASDAQ
TOI
Oncology Institute, INC
10-K: The Oncology Institute Reports Fiscal Year 2024 Results, Navigates Market Challenges
The Oncology Institute's 10-K filing reveals a year of revenue growth tempered by net losses and strategic shifts in a dynamic healthcare landscape.
NASDAQ
TOI
Oncology Institute, INC
10-K/A: Oncology Institute Files Amended 10-K to Correct Certification Omissions
The Oncology Institute has filed an amendment to its 2023 annual report to correct omissions in the certifications of its CEO and CFO regarding internal controls over financial reporting.
NASDAQ
TOI
Oncology Institute, INC
10-K/A: The Oncology Institute Files Amended 10-K to Include Omitted Part III Information
The Oncology Institute, Inc. has filed an amendment to its annual report on Form 10-K to include previously omitted information regarding directors, executive officers, and corporate governance.
NASDAQ
TOI
Oncology Institute, INC
10-K: The Oncology Institute Details Capital Stock Structure and Warrant Terms in SEC Filing
The Oncology Institute's 10-K filing provides a detailed description of its capital stock, including common stock and redeemable warrants, outlining shareholder rights and warrant terms.